Consensus on COVID-19 Vaccination in Pediatric Oncohematological Patients, on Behalf of Infectious Working Group of Italian Association of Pediatric Hematology Oncology
Authors:
- Simone CesaroSimone Cesaro
- Paola MuggeoPMPaola Muggeo
- Daniele ZamaDZDaniele Zama
- Monica CelliniMCMonica Cellini
- Katia PerruccioKPKatia Perruccio
- Antonella ColombiniACAntonella Colombini
- Francesca CarraroFCFrancesca Carraro
- Maria Grazia PetrisMPMaria Grazia Petris
- Valeria PetroniVPValeria Petroni
- Maurizio MascarinMMMaurizio Mascarin
- Francesco BaccelliFBFrancesco Baccelli
- Elena SonciniESElena Soncini
Open Access
- 24 February 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (5) , 1235
Abstract
Vaccines represent the best tool to prevent the severity course and fatal consequences of the pandemic by the new Coronavirus 2019 infection (SARS-CoV-2). Considering the limited data on vaccination of pediatric oncohematological patients, we developed a Consensus document to support the Italian pediatric hematological oncological (AIEOP) centers in a scientifically correct communication with families and patients and to promote vaccination. The topics of the Consensus were: SARS-CoV-2 infection and disease (COVID-19) in the pediatric subjects; COVID-19 vaccines (type, schedule); who and when to vaccinate; contraindications and risk of serious adverse events; rare adverse events; third dose and vaccination after COVID-19; and other general prevention measures. Using the Delphi methodology for Consensus, 21 statements and their corresponding rationale were elaborated and discussed with the representatives of 31 centers, followed by voting. A high grade of Consensus was obtained on topics such as the potential risk of severe COVID-19 outcome in pediatric oncohematological patients, the need for vaccination as a preventative measure, the type, schedule and booster dose of vaccine, the eligibility of the patients for vaccination, and the timing, definition, and management of contraindications and serious adverse events, and other general prevention measures. All 21 of the statements were approved. This consensus document highlights that children and adolescents affected by hematological and oncological diseases are a fragile category. Vaccination plays an important role to prevent COVID-19, to permit the regular administration of chemotherapy or other treatments, to perform control visits and hospital admissions, and to prevent treatment delays.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Screening for SARS‐CoV‐2 infection in pediatric oncology patients during the epidemic peak in ItalyPediatric Blood & Cancer, 2020
- Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019
- Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019
- Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) projectHaemophilia, 2019
- Immune checkpoint inhibitors and cardiovascular toxicityThe Lancet Oncology, 2018
- Varicella vaccination in pediatric oncology patients without interruption of chemotherapyJournal of Clinical Virology, 2016
- Guidelines on Vaccinations in Paediatric Haematology and Oncology PatientsBioMed Research International, 2014
- Subacute Anthracycline CardiotoxicityHeart, Lung and Circulation, 2006
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Pericarditis induced by high-dose cytosine arabinoside chemotherapyAnnals of Hematology, 1997